Gene-modified whole tumor cells are promising immunotherapeutic approaches. Creative Biolabs provides a powerful platform to engineer prostate cancer cell PC-3 for cancer immunotherapy.

Introduction of PC-3 Cell Line

PC3 cells are completely undifferentiated, are highly tumorigenic and metastatic, and have been considered the most malignant prostate cancer cell line. The cell line was isolated from grade IV prostate cancer bone metastases of a 62-year-old male Caucasian. PC3 cells are highly aggressive both in vitro and in vivo. They have features that are characteristic of prostatic small cell (neuroendocrine) carcinoma (SCNC). PC3 cells do not express androgen receptor (AR) and prostate-specific antigen (PSA) and their proliferation are independent of androgen. Therefore, the PC3 cell line has also been used to represent castration-resistant tumors and is widely used in research on androgen-resistant prostate and aggressive cancer. Furthermore, LNCaP sublines have been generated to provide the most clinically relevant tissue culture tools to date.

• Characteristics of PC-3 Cell Line

Studies Performed with Engineered PC-3 Cell Line

Researchers have designed cancer vaccines based on PC3 and LNCaP cells that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). Phase 3 trials in patients with advanced, metastatic, hormone-refractory prostate cancer are underway.

Engineering PC-3 Cell Service

Cytokine gene-modified tumor cells have been widely studied in the immunotherapy of cancer, including melanoma, prostate cancer, and colorectal cancer. Engineered tumor cells express a large number of immunostimulatory molecules to evoke potent, specific, and long-lasting anti-tumor immunity. Several studies have evaluated the capacity of engineered tumor cells with immunostimulatory cytokines (such as GM-CSF, IFN-γ, and IL-2). Focusing on the most promising frontiers, Creative Biolabs has established a platform for cancer immunotherapy. There is great promise that this platform can be harnessed to target many different cancers. We are dedicated to engineering PC-3 cells with various cytokines, including:

Other promising strategies for self-destruction, turning cancer cells against themselves, have been established. Based on your project needs, our scientific team integrates the latest approaches and offers off-of-shelf and customized solutions to quickly establish and advance your projects.

Highlights:

• Full-service scope and start at any stage upon request
• Flexible options on engineering methods
• Deliver detailed service reports and provide technical support
• Team with experience in multiple production platforms

Please feel free to contact us, and one of our experts will contact you to discuss how we can help.

Reference

1. Simons, J.W.; Sacks, N. Granulocyte-macrophage colony-stimulating factor− transduced allogeneic cancer cellular immunotherapy: The GVAX^® vaccine for prostate cancer//Urologic Oncology: Seminars and Original Investigations. Elsevier. 2006, 24(5): 419-424

For Research Use Only | Not For Clinical Use